Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q1 FY25 Earnings Presentation
15 slides from Glenmark Pharmaceuticals's earnings presentation, Aug 14, 2024
Slide 1: Investor Presentation: Q1 FY25
Investor Presentation: Q1 FY25 14 August 2024
Slide 2: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 3: Q1 FY25 Summary
Q1 FY25 Summary “Our strong start to the new financial year reflects our robust revenue growth across key regions and solid operational Consolidated Revenue of Rs. 32,442 Mn; YoY growth of 6.9% performance, leading to a significantly improved margin India Business YoY growth of 11.9% profile. Ou
Slide 4: Consolidated Revenues – Q1 FY25
Consolidated Revenues – Q1 FY25 First Quarter ended June 30 Fourth Quarter ended March 31 YoY Growth QoQ Growth Rs Mn FY 2024-25 FY 2023-24 FY 2023-24 (%) (%) India 11,962 10,693 11.9% 9,391 27.4% North America 7,808 8,183 -4.6% 7,557 3.3% Europe 6,957 5,732 21.4% 6,118 13.7% Rest of the World 1 5,7
Slide 5: Revenue Across Key Geographies – Q1 FY25
Revenue Across Key Geographies – Q1 FY25 1% 0% 0% 18% 18% 24% 31% 35% 37% Q1 FY24 Q4 FY24 Q1 FY25 19% 21% 20% 25% 27% 24% India Europe Other Revenue North America ROW 5 ©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved
Slide 6: P&L Highlights
P&L Highlights Rs. Mn Q1 FY25 Q1 FY24 %YoY Q4 FY24 %QoQ Revenues from Operations 32,442 30,361 6.9% 30,630 5.9% Gross Margin 21,341 18,483 20,674 Gross Margin (%) 65.8% 60.9% 67.5% EBITDA 5,882 4,374 34.5% 5,043 16.6% EBITDA Margin (%) 18.1% 14.4% 16.5% Other Income (exp) 315 197 7,732 Exceptional g
Slide 7: India
Q1 FY25 37% India Collaborated with Beigene for One of the fastest-growing marketing and distribution of companies in the IPM as per novel oncology products - IQVIA June 2024 Tislelizumab and Zanubrutinib Key Highlights Revenue (INR million) Glenmark’s India business continued to outperform the ov
Slide 8: North America
Q1 FY25 37% North America ANDA for gFlovent® 44mcg 50 ANDAs pending for approval, pMDI filed in May 2024 including 21 Para IV applications Key Highlights Revenue (INR million) Overall business growth remained challenging on account of lack of new product QoQ: 3.3% YoY: -4.6% launches and delay in
Slide 9: Europe
Q1 FY25 37% Europe Continued growth momentum RYALTRIS® continues to scale up driven by all markets and increase market share Key Highlights Revenue (INR million) YoY: 21.4% All the key countries recorded healthy double-digit growth QoQ: 13.7% The key markets in the CEE region, including the Czec
Slide 10: Rest Of the World (ROW)
Q1 FY25 37% Rest Of the World (ROW)1 Strong performance in Russia RYALTRIS® continues to scale up and LATAM and increase market share Key Highlights Revenue (INR million) YoY: 3.3% Russia: secondary sales recorded growth of 15.7% and 16.9% in Q1 FY25 and QoQ: -24.2% MAT June 2024. Glenmark ranked
Slide 11: Creating Global Brands – RYALTRIS®
Creating Global Brands – RYALTRIS® As of June 2024, marketing applications for RYALTRIS® have been submitted in more than 90 countries across the world and the product has been commercialized in 40 markets. Further, it has received approval and will be launched in 10-11 additional markets over the
Slide 12: Creating Global Brands – ENVAFOLIMAB & WINLEVI®
Creating Global Brands – ENVAFOLIMAB & WINLEVI® ENVAFOLIMAB The Company announced the signing of a license agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd (Jiangsu Alphamab) and 3D Medicines (Beijing) Co., Ltd. (3DMed) for Envafolimab for India, Asia Pacific, Middle East and Africa, Ru
Slide 13: ICHNOS GLENMARK INNOVATION
ICHNOS GLENMARK INNOVATION * ISB 1342 – Phase 1 clinical study is currently suspended; future strategy is to out-license the asset and allow a potential partner to continue further development TREAT: Trispecific Engagement by Antibodies based on the T cell receptor BEAT: Bispecific Engagement by Ant
Slide 14: Key objectives for FY25
Key objectives for FY25 1 Consolidated revenue: Rs. 1,35,000 – 1,40,000 million 2 R&D investment: 7-7.25% of total sales 3 EBITDA margin: ~19% 4 Consolidated CAPEX: Rs. 7,000 million 5 Target double-digit PAT margin 14 ©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved
Slide 15: Thank You
G Glenmark Thank You
Glenmark Pharmaceuticals — Q1 FY25 Earnings Presentation on 6ix